Thrombomodulin-dependent effect of factor v Leiden mutation on the cross-linking of α2-plasmin inhibitor to fibrin and its consequences on fibrinolysis

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages 528-534

  Koncz, Zsuzsa ^a   Bagoly, Zsuzsa ^a   Haramura, Gizella ^a   Mezei, Zoltán A ^a   Muszbek, László ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

2 plasmin inhibitor; factor V Leiden mutation; factor XIII; fibrinolysis; thrombin activatable fibrinolysis inhibitor

Indexed keywords

ALPHA 2 ANTIPLASMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; PHOSPHOLIPID; RECOMBINANT THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING FACTOR 5 LEIDEN GENE; BLOOD SAMPLING; CROSS LINKING; DENSITOMETRY; FIBRINOLYSIS; GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; TURBIDIMETRY; WESTERN BLOTTING;

ALPHA-2-ANTIPLASMIN; CROSS-LINKING REAGENTS; FACTOR V; FIBRIN; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; MUTATION; THROMBOMODULIN;

EID: 84865208467     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.05.019     Document Type: Article

References (41)

1. B. Dahlback Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism Blood 85 1995 607 614
2. F.R. Rosendaal Venous thrombosis: A multicausal disease Lancet 353 1999 1167 1173
3. R.M. Bertina, B.P. Koeleman, T. Koster, F.R. Rosendaal, R.J. Dirven, and H. de Ronde Mutation in blood coagulation factor V associated with resistance to activated protein C Nature 369 1994 64 67
4. K. Segers, B. Dahlback, and G.A. Nicolaes Coagulation factor V and thrombophilia: Background and mechanisms Thromb Haemost 98 2007 530 542
5. B. Dahlback Advances in understanding pathogenic mechanisms of thrombophilic disorders Blood 112 2008 19 27
6. C. van 't Veer, M. Kalafatis, R.M. Bertina, P. Simioni, and K.G. Mann Increased tissue factor-initiated prothrombin activation as a result of the Arg506 - > Gln mutation in factor VLEIDEN J Biol Chem 272 1997 20721 20729
7. E. Thorelli, R.J. Kaufman, and B. Dahlback Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V Blood 93 1999 2552 2558
8. E. Castoldi, J.M. Brugge, G.A. Nicolaes, D. Girelli, G. Tans, and J. Rosing Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations Blood 103 2004 4173 4179
9. C. van 't Veer, and K.G. Mann Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II J Biol Chem 272 1997 4367 4377
10. C.T. Esmon Inflammation and the activated protein C anticoagulant pathway Semin Thromb Hemost 32 Suppl. 1 2006 49 60
11. L. Bajzar, R. Manuel, and M.E. Nesheim Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor J Biol Chem 270 1995 14477 14484
12. J. Morser, E.C. Gabazza, T. Myles, and L.L. Leung What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 8 2010 868 876
13. M. Nesheim, W. Wang, M. Boffa, M. Nagashima, J. Morser, and L. Bajzar Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis Thromb Haemost 78 1997 386 391
14. M. Nesheim Thrombin and fibrinolysis Chest 124 2003 33S 39S
15. L.O. Mosnier, and B.N. Bouma Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis Arterioscler Thromb Vasc Biol 26 2006 2445 2453
16. L. Bajzar, M. Kalafatis, P. Simioni, and P.B. Tracy An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden J Biol Chem 271 1996 22949 22952
17. L.O. Mosnier, J.C. Meijers, and B.N. Bouma Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin Thromb Haemost 85 2001 5 11
18. L. Muszbek, Z. Bagoly, Z. Bereczky, and E. Katona The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis Cardiovasc Hematol Agents Med Chem 6 2008 190 205
19. L. Muszbek, Z. Bereczky, Z. Bagoly, I. Komaromi, and E. Katona Factor XIII: A coagulation factor with multiple plasmatic and cellular functions Physiol Rev 91 2011 931 972
20. J. Polgar, I. Lerant, L. Muszbek, and R. Machovich Thrombomodulin inhibits the activation of factor XIII by thrombin Thromb Res 43 1986 685 690
21. H. Philippou, J. Rance, T. Myles, S.W. Hall, R.A. Ariens, and P.J. Grant Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate J Biol Chem 278 2003 32020 32026
22. Z. Koncz, Z. Bagoly, G. Haramura, Z.A. Mezei, and L. Muszbek Thrombomodulin-dependent effect of factor V(Leiden) mutation on factor XIII activation Thromb Res 2011 10.1016/j.thromres.2011.06.030
23. I. Balogh, G. Szoke, L. Karpati, U. Wartiovaara, E. Katona, and I. Komaromi Val34Leu polymorphism of plasma factor XIII: Biochemistry and epidemiology in familial thrombophilia Blood 96 2000 2479 2486
24. R.A. Ariens, H. Philippou, C. Nagaswami, J.W. Weisel, D.A. Lane, and P.J. Grant The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure Blood 96 2000 988 995
25. A.H. Shemirani, G. Haramura, Z. Bagoly, and L. Muszbek The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma Biochim Biophys Acta 1764 2006 1420 1423
26. V. Schroder, and H.P. Kohler Effect of factor XIII Val34Leu on alpha2-antiplasmin incorporation into fibrin Thromb Haemost 84 2000 1128 1130
27. B.P. Koeleman, P.H. Reitsma, C.F. Allaart, and R.M. Bertina Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families Blood 84 1994 1031 1035
28. A.H. Shemirani, and L. Muszbek Rapid detection of the factor XIII Val34Leu (163 G->T) polymorphism by real-time PCR using fluorescence resonance energy transfer detection and melting curve analysis Clin Chem Lab Med 42 2004 877 879
29. K.E. Brummel, S. Butenas, and K.G. Mann An integrated study of fibrinogen during blood coagulation J Biol Chem 274 1999 22862 22870
30. B. Dahlback Human coagluation factor V purification and thrombin-catalyzed activation J Clin Invest 66 1980 583 591
31. A.W. Dielis, W.M. Balliel, R. van Oerle, W.T. Hermens, H.M. Spronk, and H. Ten Cate Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A Haematologica 93 2008 1351 1357
32. Y. Sakata, and N. Aoki Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor J Clin Invest 65 1980 290 297
33. A.C. Parker, L.V. Mundada, A.H. Schmaier, and W.P. Fay Factor VLeiden inhibits fibrinolysis in vivo Circulation 110 2004 3594 3598
34. K.N. Lee, K.W. Jackson, V.J. Christiansen, K.H. Chung, and P.A. McKee A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion Blood 103 2004 3783 3788
35. Y. Sumi, Y. Ichikawa, Y. Nakamura, O. Miura, and N. Aoki Expression and characterization of pro alpha 2-plasmin inhibitor J Biochem 106 1989 703 707
36. K. Bangert, A.H. Johnsen, U. Christensen, and S. Thorsen Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma Biochem J 291 Pt 2 1993 623 625
37. S. Kimura, and N. Aoki Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor J Biol Chem 261 1986 15591 15595
38. Y. Sakata, and N. Aoki Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis J Clin Invest 69 1982 536 542
39. S.R. Fraser, N.A. Booth, and N.J. Mutch The antifibrinolytic function of factor XIII is exclusively expressed through alpha-antiplasmin cross-linking Blood 117 2011 6371 6374
40. L.O. Mosnier, M.G. Elisen, B.N. Bouma, and J.C. Meijers Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation Thromb Haemost 86 2001 1057 1064
41. L.O. Mosnier, J.C. Meijers, and B.N. Bouma The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis Thromb Haemost 86 2001 1040 1046